# Biotech Daily Digest ‚Äî 2025-09-10

**28 items from 3 sources**

## Summary by Source

- Endpoints News: 7 items
- Fierce Biotech: 4 items
- arXiv q-bio: 17 items


## Endpoints News

- **[PMV to pursue FDA approval in ovarian cancer; Amylyx reveals $175M offering](https://endpoints.news/pmv-to-pursue-fda-approval-in-ovarian-cancer-amylyx-reveals-175m-offering/)**  
  _Wed, 10 Sep 2025 14:04:01 +0000_  
  Plus, news about CAMP4 Therapeutics, Serina Therapeutics, Kriya Therapeutics, Cutiss, Dianthus Therapeutics, Alnylam and Eyexora:

 üî¨ PMV touts Phase 2 data in p53 mutation cancers: In a 97-patient trial for rezatapopt, PMV

- **[FDA blocks US imports from Sun Pharma's Halol site over repeated issues](https://endpoints.news/fda-blocks-us-imports-from-sun-pharmas-halol-site-over-repeated-issues/)**  
  _Wed, 10 Sep 2025 13:59:27 +0000_  
  Sun Pharma‚Äôs troubled Halol factory located in Gujarat, India has been hit with an "official action indicated‚Äù classification after FDA inspectors found repeated issues with contamination and the facility's equipment.

 An OAI classification means the ...

- **[Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 study](https://endpoints.news/chinese-crispr-company-yoltech-raises-45m-as-it-plans-for-first-phase-3-study/)**  
  _Wed, 10 Sep 2025 13:39:50 +0000_  
  YolTech Therapeutics, a prolific Chinese biotech that‚Äôs already begun testing four CRISPR gene editing therapies in small clinical studies, raised a $44.5 million Series B to test several more genetic medicines in humans and potentially ...

- **[Odyssey gets $213M Series D after backing out of IPO](https://endpoints.news/odyssey-gets-213m-series-d-after-backing-out-of-ipo/)**  
  _Wed, 10 Sep 2025 12:00:00 +0000_  
  Odyssey Therapeutics has pulled together a nine-figure private funding round after halting its public market ambitions earlier this year.

 The biotech raised $213 million from its existing investors and a batch of ...

- **[J&J‚Äôs ‚Äòpretzel‚Äô drug-device therapy wins US approval for certain bladder cancers](https://endpoints.news/jjs-pretzel-drug-device-therapy-wins-us-approval-for-certain-bladder-cancers/)**  
  _Wed, 10 Sep 2025 11:01:02 +0000_  
  Johnson & Johnson has secured FDA approval for a drug-device approach for bladder cancer that could spare patients from having to get their bladders surgically removed.

 The company‚Äôs TAR-200 was greenlit for non-muscle invasive bladder ...

- **[Regeneron and Sandoz patent deal clears path for Eylea biosimilar in 2026](https://endpoints.news/regeneron-and-sandoz-patent-deal-clears-path-for-eylea-biosimilar-in-2026/)**  
  _Tue, 09 Sep 2025 16:33:37 +0000_  
  Sandoz can sell its biosimilar version of Regeneron‚Äôs Eylea in the US by the end of 2026, following a patent settlement between the two companies.

 The generic drugmaker announced Tuesday that ...

- **[Regeneron‚Äôs promising antibody for cat, birch allergies; Ascletis targets quarterly GLP-1 shot](https://endpoints.news/regenerons-promising-antibody-for-cat-birch-allergies-ascletis-targets-quarterly-glp-1-shot/)**  
  _Tue, 09 Sep 2025 14:51:27 +0000_  
  Plus, news about Anavex, Alnylam, Rapport Therapeutics, Dianthus Therapeutics, Ultragenyx, Atom Therapeutics, Alchemab, BioMarin, Amgen, Kyowa Kirin and Bristol Myers Squibb:

 ü§ß Regeneron‚Äôs allergy drugs clear Phase 3 trials: The company‚Äôs allergen-blocking antibody candidates  ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/mei-pharma-leaves-biotech-woes-behind-rebrand-crypto-company" hreflang="en">MEI Pharma leaves biotech woes behind to rebrand as crypto company</a>](https://www.fiercebiotech.com/biotech/mei-pharma-leaves-biotech-woes-behind-rebrand-crypto-company)**  
  _Sep 10, 2025 10:01am_  
  From now on, MEI Pharma‚Äîpreviously best known for its clinical-stage leukemia drug‚Äîwill be called Lite Strategy.

- **[<a href="https://www.fiercebiotech.com/biotech/trump-admin-mulls-severe-restrictions-us-pharmas-securing-chinese-meds-nyt" hreflang="en">Trump admin mulls 'severe restrictions' on US pharmas licensing Chinese meds: NYT</a>](https://www.fiercebiotech.com/biotech/trump-admin-mulls-severe-restrictions-us-pharmas-securing-chinese-meds-nyt)**  
  _Sep 10, 2025 8:43am_  
  The Trump administration is considering putting ‚Äúsevere restrictions‚Äù on the increasing flow of investigational drugs from China, according to reporting by The New York Times.

- **[<a href="https://www.fiercebiotech.com/medtech/ronovo-surgical-raises-67m-modular-laparoscopic-robot-jj-backing" hreflang="en">Ronovo Surgical raises $67M for modular laparoscopic robot with J&amp;J backing</a>](https://www.fiercebiotech.com/medtech/ronovo-surgical-raises-67m-modular-laparoscopic-robot-jj-backing)**  
  _Sep 9, 2025 1:33pm_  
  The Shanghai-based company said it has inked a collaboration agreement with J&J‚Äôs local subsidiary for its recently approved Carina platform.

- **[<a href="https://www.fiercebiotech.com/biotech/capricor-shares-response-cell-therapy-denial-after-fda-publicly-releases-rejection-letter" hreflang="en">FDA misinterpreted efficacy data that prompted DMD rejection, Capricor claims</a>](https://www.fiercebiotech.com/biotech/capricor-shares-response-cell-therapy-denial-after-fda-publicly-releases-rejection-letter)**  
  _Sep 9, 2025 11:13am_  
  Capricor Therapeutics has publicly released its July response to the FDA's rejection of its Duchenne muscular dystrophy cell therapy deramiocel after the agency included deramiocel in a new batch of complete response letters (CRLs) released on Sept. 4.


## arXiv q-bio

- **[Association of Timing and Duration of Moderate-to-Vigorous Physical Activity with Cognitive Function and Brain Aging: A Population-Based Study Using the UK Biobank](https://arxiv.org/abs/2509.06969)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2509.06969v1 Announce Type: new 
Abstract: Physical activity is a modifiable lifestyle factor with potential to support cognitive resilience. However, the association of moderate-to-vigorous physical activity (MVPA) intensity, and timing, with cognitive function and region-specific brain structure remain poorly‚Ä¶

- **[Quantifying the Impact of Epigallocatechin Gallate and Piperine on D. tigrina Regeneration](https://arxiv.org/abs/2509.06972)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2509.06972v1 Announce Type: new 
Abstract: The increasing global cancer burden necessitates exploration of effective and affordable treatments. Epigallocatechin gallate (EGCG), a green tea catechin, and piperine, a black pepper alkaloid, have demonstrated promising anti-cancer properties. Leveraging the regenera‚Ä¶

- **[Towards automatizing detection and quantification of intestinal metaplasia: a multi-expert comparative study](https://arxiv.org/abs/2509.06991)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2509.06991v1 Announce Type: new 
Abstract: Current gastric cancer risk systems are prone to errors since they evaluate a visual estimation of intestinal metaplasia percentages to assign a risk. This study presents an automated method to detect and quantify intestinal metaplasia using deep learning models as well‚Ä¶

- **[Artificial Intelligence as an Opportunity for the Science of Consciousness: A Dual-Resolution Framework](https://arxiv.org/abs/2509.07001)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2509.07001v1 Announce Type: new 
Abstract: The encounter of artificial intelligence with consciousness research is often framed as a challenge: could this science determine whether such systems are conscious? We suggest it is equally an opportunity to expand and test the scope of existing theories of consciousne‚Ä¶

- **[Computational Concept of the Psyche](https://arxiv.org/abs/2509.07009)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2509.07009v1 Announce Type: new 
Abstract: The article provides an overview of approaches to modeling the human psyche in the perspective of building an artificial one. Based on the review, a concept of cognitive architecture is proposed, where the psyche is considered as an operating system of a living or artif‚Ä¶

- **[Normative Modelling in Neuroimaging: A Practical Guide for Researchers](https://arxiv.org/abs/2509.07237)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2509.07237v1 Announce Type: new 
Abstract: Normative modelling is an increasingly common statistical technique in neuroimaging that estimates population-level benchmarks in brain structure. It enables the quantification of individual deviations from expected distributions whilst accounting for biological and tec‚Ä¶

- **[Finding low-complexity DNA sequences with longdust](https://arxiv.org/abs/2509.07357)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2509.07357v1 Announce Type: new 
Abstract: Motivation: Low-complexity (LC) DNA sequences are compositionally repetitive sequences that are often associated with increased variant density and variant calling artifacts. While algorithms for identifying LC sequences exist, they either lack rigorous mathematical fou‚Ä¶

- **[Magnetic Resonance Imaging Virtual Liver Biopsy Using Radiomics Analysis for the Assessment of Chronic Liver Disease](https://arxiv.org/abs/2509.07516)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2509.07516v1 Announce Type: new 
Abstract: Objectives: The role of advanced diffusion-weighted imaging (DWI) in chronic liver disease (CLD) has not been fully studied. Chronic liver disease (CLD) is a progressive deterioration of liver functions, caused by one or more etiology. This study was aimed to investigat‚Ä¶

- **[Unveiling Biological Models Through Turing Patterns](https://arxiv.org/abs/2509.07458)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2509.07458v1 Announce Type: cross 
Abstract: Turing patterns play a fundamental role in morphogenesis and population dynamics, encoding key information about the underlying biological mechanisms. Yet, traditional inverse problems have largely relied on non-biological data such as boundary measurements, neglectin‚Ä¶

- **[LSMTCR: A Scalable Multi-Architecture Model for Epitope-Specific T Cell Receptor de novo Design](https://arxiv.org/abs/2509.07627)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2509.07627v1 Announce Type: cross 
Abstract: Designing full-length, epitope-specific TCR {\alpha}\b{eta} remains challenging due to vast sequence space, data biases and incomplete modeling of immunogenetic constraints. We present LSMTCR, a scalable multi-architecture framework that separates specificity from con‚Ä¶

- **[BDPM: A Machine Learning-Based Feature Extractor for Parkinson's Disease Classification via Gut Microbiota Analysis](https://arxiv.org/abs/2509.07723)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2509.07723v1 Announce Type: cross 
Abstract: Background: Parkinson's disease remains a major neurodegenerative disorder with high misdiagnosis rates, primarily due to reliance on clinical rating scales. Recent studies have demonstrated a strong association between gut microbiota and Parkinson's disease, suggesti‚Ä¶

- **[Triplication: an important component of the modern scientific method](https://arxiv.org/abs/2201.10960)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2201.10960v3 Announce Type: replace 
Abstract: A scientific-study protocol, as defined here, is designed to deliver results from which inductive inference is allowed. In the nineteenth century, triplication was introduced into the plant sciences and Fisher's p<0.05 rule (1925) was incorporated into a triple-resu‚Ä¶

- **[Explainable Metrics for the Assessment of Neurodegenerative Diseases through Handwriting Analysis](https://arxiv.org/abs/2409.08303)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2409.08303v3 Announce Type: replace 
Abstract: Motor dysfunction is a common sign of neurodegenerative diseases (NDs) such as Parkinson's disease (PD) and Alzheimer's disease (AD), but may be difficult to detect, especially in the early stages. In this work, we examine the behavior of a wide array of explainable‚Ä¶

- **[Mathematical model of Nucleocytoplasmic Transport and Nuclear-to-Cell Ratio in a growing cell](https://arxiv.org/abs/2504.06452)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2504.06452v2 Announce Type: replace 
Abstract: It has been observed that the growth of the nucleus and the cytoplasm is coordinated during cell growth, resulting in a nearly constant nuclear-to-cell volume ratio (N/C) throughout the cell cycle. Previous studies have shown that the N/C ratio is determined by the‚Ä¶

- **[A Probabilistic Framework for Imputing Genetic Distances in Spatiotemporal Pathogen Models](https://arxiv.org/abs/2506.09076)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2506.09076v3 Announce Type: replace 
Abstract: Pathogen genome data offers valuable structure for spatial models, but its utility is limited by incomplete sequencing coverage. We propose a probabilistic framework for inferring genetic distances between unsequenced cases and known sequences within defined transmi‚Ä¶

- **[BioNeMo Framework: a modular, high-performance library for AI model development in drug discovery](https://arxiv.org/abs/2411.10548)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2411.10548v5 Announce Type: replace-cross 
Abstract: Artificial Intelligence models encoding biology and chemistry are opening new routes to high-throughput and high-quality in-silico drug development. However, their training increasingly relies on computational scale, with recent protein language models (pLM) t‚Ä¶

- **[Route to Chaos in Multi-Species Ecosystems](https://arxiv.org/abs/2503.16999)**  
  _Wed, 10 Sep 2025 00:00:00 -0400_  
  arXiv:2503.16999v2 Announce Type: replace-cross 
Abstract: We investigate species-rich mathematical models of ecosystems. While much of the existing literature focuses on the properties of equilibrium fixed points, persistent dynamics (e.g., limit cycles or chaos) have also been observed, both in natural or lab-contro‚Ä¶
